KOSDAQ - Delayed Quote KRW

Gencurix Inc. (229000.KQ)

Compare
2,520.00 -75.00 (-2.89%)
At close: October 18 at 3:30 PM GMT+9

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.
NameTitlePayExercisedYear Born
Sung-Rai Cho Chief Executive Officer -- -- --

Gencurix Inc.

Hanhwa Bizmetro
4th Floor 242 Digital-ro Guro-gu
Seoul, 152-733
South Korea
82 2 2621 7038 https://www.gencurix.com
Sector: 
Healthcare
Full Time Employees: 
69

Description

Gencurix Inc. provide diagnostic solutions in South Korea. Its products include GenesWell BCT, a prognosis diagnostic test for breast cancer; GenesWell ddEGFR Mutation Test, a companion test for lung cancer; Droplex, a genetic test that detects DNA mutations; eDX, an early diagnosis for cancer with liquid biopsy; GenePro COVID-19 detection test; GenePro SARS-CoV-2 Test kit; GenoCTC (circulating tumor cell isolator); GenePro LAMP test solution for rapid, convenient and simple detection of various infectious diseases; and GenePro LAMP Cycler, a device for loop-mediated isothermal amplification. The company was founded in 2011 and is headquartered in Seoul, South Korea.

Corporate Governance

Gencurix Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 12, 2024 at 10:59 AM UTC - November 18, 2024 at 12:00 PM UTC

Gencurix Inc. Earnings Date

Recent Events